Purdue Pharma
As of the edition of 20 October 2026, Purdue Pharma runs 15 drugs, 11 of them marketed; it is on route A at 1 target and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 15 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Morphine | none listed | 2 |
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Methylphenidate | none listed | 11 |
| Oxycodone | none listed | 2 |
| Naloxone | none listed | 10 |
| Tramadol | none listed | 3 |
| Hydromorphone | none listed | 1 |
| Levobupivacaine | none listed | 0 |
| Hydrocodone | none listed | 9 |
| Codeine | none listed | 8 |
| Nalmefene | none listed | 9 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 3 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Purdue Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Bones, joints and muscles: 3 trials led
- Nervous system: 1 trials led